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High quality histopathology is essential for the success of clinical trials. Histopathologists 
have a detailed understanding of tumour biology and mechanisms of disease, as well as 
practical knowledge of optimal tissue handling and logistical service requirements for study 
delivery such as biomarker evaluation, tissue acquisition and turnaround times. As such, 
histopathologist input is essential through every stage of research and clinical trials from 
concept development and study design, through trial delivery, to analysis and dissemination 
of results. Patient recruitment to trials takes place across all healthcare settings meaning 
histopathologists make an invaluable contribution to clinical trials as part of their routine day 
to day work that often goes unrecognised. More complex evaluation of surgical specimens in 
the neoadjuvant setting and ever-expanding minimum datasets add to the workload of every 
histopathologist, not just academic pathologists in tertiary centres. This is occurring against a 
backdrop of increasing workload pressures and a worldwide shortage of histopathologists and 
biomedical scientists. Providing essential histopathology support for trials at grassroots level 
requires funding for adequate resources including histopathologist time, education and 
training, biomedical scientist and administrative support, and greater recognition of the 
contribution made by histopathology. This paper will discuss the many ways 
histopathologists are involved in clinical trials, the challenges faced in meeting the additional 
demands posed by trial participation, and potential ways to address this with a special 
emphasis on the UK model and the Cellular-Molecular Pathology Initiative (CM-Path). 
 
 





High quality histopathology is a critical component of many clinical trials. Histopathologists 
have a detailed understanding of tumour biology and mechanisms of disease as well as 
practical knowledge of optimal tissue handling and the technical considerations behind 
testing protocols. As such histopathologist input is essential through every stage of research 
and clinical trials from concept development, through delivery to analysis and dissemination 
of results (figure 1/ supplementary table 1).  
Histopathologist participation is key in ensuring correct patient selection. This incorporates 
traditional tumour classification by morphological subtyping, as well as assessment of 
biomarkers using immunohistochemistry and molecular techniques. Neoadjuvant therapy is 
increasingly used in trials, with the advantage of smaller, more cost-effective studies with 
pathological complete response (pCR) as a surrogate of long-term survival benefit providing 
earlier results1-3. Hence, in neoadjuvant trials it is the histopathologist that provides the 
primary trial outcome. Accurate assessment of response to therapy requires detailed 
macroscopy, thorough sampling and precise microscopic evaluation4. In both correctly 
identifying patients for trials and determining outcome measures, results must be 
reproducible requiring precise definitions and stringent quality assurance (QA) protocols. 
In addition, new biomarkers identified by trials need to be incorporated into routine 
diagnostic practice in order for novel agents to become standard therapy. This requires 
standardised protocols for assessment, training in interpretation, ongoing QA to ensure 
equivalent results within and between centres, and provision of adequate resources and 
funding  
Patients are recruited to trials in all healthcare settings meaning histopathologists make an 




evaluation of surgical specimens and ever-expanding minimum datasets add to the workload 
of every histopathologist, not just academic pathologists in tertiary centres. Providing 
essential histopathology support for trials at grassroots level requires funding for adequate 
resources including histopathologist time, education and training, biomedical scientist and 
administrative support, and greater recognition of the contribution made by pathology.  
This paper will discuss the many ways histopathologists are involved in clinical trials and the 
challenges faced in meeting the additional demands posed by trial participation, and ways to 
address this with a special emphasis on the UK model. 
Histopathologist role in trials 
The roles of histopathologists in research include:  
Research development/ generation  
With their understanding of basic biology and the direct observation of morphological 
features under the microscope, histopathologists are well positioned to identify key questions 
and take the lead in initiating and leading clinical research as a Chief Investigator. This 
entails a significant time commitment, from procuring funding in today’s highly competitive 
grant environment, access to staff and facilities to deliver the project, and analysis and 
dissemination of results, and is predominantly but not exclusively undertaken by individuals 
with dual clinical and academic appointments in larger centres. This is becoming an 
increasingly rare occurrence internationally due to dwindling numbers of academic 
pathologists. 
More commonly, histopathologists make a significant contribution to trial design as part of a 
multidisciplinary team (collaborator/ co-investigator). Histopathologists provide unique 
clinical and analytical expertise that is vital in the initial development and design of clinical 




of diagnostic pathways, biomarkers [selection, interpretation, limitations, QA and 
reproducibility], tissue access and real-world restrictions including turnaround times and 
logistics of sample acquisition. The histopathologist should be consulted across the entire 
development programme, including target and or biomarker validation, attending scientific 
advice meetings with regulatory authorities, writing the clinical trial protocol and study 
report, and ensuring that histopathology standards and the clinicopathological interpretation 
of the research data are conveyed consistently and in accordance with international and 
national standards (e.g. REMARK5, International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use (ICH)6, Royal College of Pathologists 
(RCPath)7). An understanding of these factors, and the associated financial costs, is crucial to 
designing a successful study. Central trial histopathologists also provide an essential link 
between the trial team and local histopathologists, without whose co-operation successful 
trial delivery is not possible.  
Whilst pathologist representation is an intrinsic part of many co-operative clinical trial groups 
internationally (for example the National Cancer Research Institute (NCRI) in the U.K., 
GEICAM/ GEICO in Spain), unfortunately it is still the exception for pathologists to be 
involved early in the trial design process. The more typical scenario is being presented with a 
complete or near complete protocol with funding already determined. The Standard Protocol 
Items: Recommendations for Interventional Trials (SPIRIT) statement aims to improve the 
completeness and quality of clinical trial protocols and has been endorsed by international 
funders, regulators, industry and researchers8. Robust and consistent interpretative pathology 
is essential as a central pillar of patient selection and tissue-based endpoint assessment in 
clinical trials, but there are currently no cogent and formalised standards for pathological 
input into trial design and delivery. Through the UK National Cancer Research Institute 




SPIRIT-Path project is developing international, consensus-based, pathology-specific 
protocol guidance as an extension to the SPIRIT statement, and the protocol for the 
supporting literature search is available from the Centre for Open Science OSF registry 9,10. 
Such guidelines will provide a mechanism for the appropriate involvement, recognition and 
funding of pathologists in clinical trials work. 
Research delivery  
Histopathology services are integral to the delivery of clinical trials, particularly those for 
oncological drug treatments. Site histopathologists provide the initial diagnosis to correctly 
determine eligibility. Tissue samples taken specifically for the trial must be carefully and 
consistently selected, embedded, processed and H&E slides cut and stained for 
histopathological assessment, e.g. to determine tumour content. Often diagnostic archive 
tissue is required to be released to a central laboratory. Archival cases must be identified, 
slides reviewed and appropriate blocks selected and retrieved, and the material securely 
delivered. In addition, histopathologists are key in the Biobanking pathway by collecting 
relevant fresh, frozen and fixed samples for various translational techniques including 
DNA/RNA extraction, cell culture, genetic testing or banking for future translational 
research. Histopathologists provide samples for Biobanks across the world facilitating 
international collaborations necessary for the global impact of translational research11. 
Histopathologists may be requested to analyse tissue samples for biomarker expression or 
assess treatment effect in tissues as an endpoint. 
Examples of how pathology involvement is instrumental to clinical trial delivery are provided 
in table 1. 
  
 




In the U.K., The Cellular Molecular Pathology Initiative (CM-Path) has been set up to 
support academic pathology and address barriers for trials and translational research. The 
clinical trials workstream has conducted several surveys of UK pathologists and identified the 
main barriers to participation in research as time constraints, lack of remuneration, and 
perceived lack of trial knowledge and skills. Feedback from pathologists in the U.S., Europe, 
Asia and Australia highlight similar issues across the globe. There is a universal lack of 
recognition of the additional workload brought by clinical trials in departmental and 
individual job planning. Depending on the nature of the trial (academic versus commercial 
sponsor) there may be some reimbursement for laboratory work such as block retrieval or 
performance of biomarkers, but this is often insufficient to cover the total costs involved, and 
excludes payment for pathologist activities such as slide review or biomarker scoring. In 
some countries, such as the U.S. and Australia, pathologist trial participation is further 
complicated by private health care systems.Adequate staffing  
Clinical trials require the input of a diverse workforce including archivists, secretaries, and 
biomedical scientists as well as histopathologists.  In many countries worldwide including the 
U.K., there is a current shortage of histopathologists and biomedical scientists12. A recent 
workforce report by the RCPath highlighted that 97% of UK laboratories are under staffed13. 
Due to this pressure delivery of essential diagnostic services and meeting clinical turnaround 
times are often prioritised over ‘extras’ such as clinical trials, which risks  impeding the 
delivery of therapeutic improvements for patients. Departmental management must ensure 
clinical trial work can be adequately resourced and carried out in a timely manner, so patients 
do not miss out on trial opportunities.  
There is great variation across histopathology departments, in the U.K. and globally, in terms 




banks with staff and resources specifically allocated to research including support of clinical 
trials. However, in the majority of departments, this additional workload must be absorbed by 
routine laboratory staff without compromising the delivery of basic diagnostic services. This 
needs to change, with dedicated time and resource set aside for consultant pathologists, 
histopathology trainees and biomedical scientists to contribute their expertise consistently 
into trials.  
There are currently no recommendations for adequate staffing for research in the UK. RCPath 
Guidelines on staffing, and workload for histopathology departments state “In departments 
with research programmes, there may be specific dissection and reporting protocols for 
research projects that take extra time compared with that for normal specimen handling. We 
recommend that the extra time taken is classified as research and that appropriate SPA time 
is allocated in the job plan”14. Since the implementation of National Institute of Health 
Research Clinical Research Networks (NIHR CRN), every National Health Service (NHS) 
Trust is now active in research so every department may be called upon to undertake these 
activities. Pathology staff job descriptions should provide clarity with regard to responsibility 
and accountability for clinical trials. Ensuring the pathology workforce has both the 
capability and capacity to support this will be challenging. In parallel, there has been a 
decline in academic pathology staff. However, the CM-Path initiative, with the support of 
other stakeholders, is working on ways to reverse this trend and increase the recognition of 
research in pathologist training and continued professional development (CPD). 
Funding sources 
As described, a histopathologist will sometimes be formally named as an investigator on a 
trial and the research grant will have funding to cover their contributions. This section 




activity in support of a trial or research study by, for example, scoring biomarkers, submitting 
tissue blocks and/or slides or completing pathology-based Case Report Forms (CRF). Many 
departments, sometimes due to lack of awareness or administrative support, complete these 
activities without seeking remuneration.  
There have been increases in both the clinical trials requiring histopathology input and in the 
overall workload of histopathology departments; for example, at University College London 
Hospital (UCLH) there are currently over 150 trials set up that require histopathology input. 
The cellular pathology lab at UCLH is run by a private company and it has a very 
comprehensive system for costing trials and for ensuring that all laboratory work is paid for. 
All new trials requiring pathology input must be registered on a portal so laboratory and 
histopathology leads are aware of their existence. However, one major problem is  
pathologist time is not costed as the pathology consultants are employed by the NHS not the 
laboratory. Similarly, the Dana Farber Cancer Institute in Boston requires pathologist review 
of all clinical trials before granting Institutional Review Board approval. These examples 
highlight the importance of local pathologist consultation prior to initiation of trials with 
respect to availability of resources, budget implications, appropriateness of protocols, and the 
need for direct pathology input where this has not already been incorporated.  
Hence, it is increasingly important that Pathology Departments understand how funding 
works for research, and ensure they receive their fair share of any funding that can be used to 
maintain and further develop trial capabilities. A detailed description of NHS research 
funding avenues is provided in Supporting Information. 
A potential problem is the lack of recognition by those developing and funding clinical trials 
as to the contribution made by histopathology and the resources involved; specific funds for 




during trial design and identified in the grant application. Funding from the trial itself, via its 
research grant and/or commercial sponsor, should cover all pure research costs incurred by a 
histopathology department for that trial. Commercial trials are expected to cover all costs to 
the NHS for research, although in practice this often covers laboratory work such as section 
cutting or immunohistochemical tests but does not incorporate pathologist time. Non-
commercial trials in the U.K., if they are on the NIHR CRN Portfolio, are eligible for NHS 
Support Costs funding provided via the local network.  
Accurate billing for pathology services can be difficult as laboratory setups differ nationally 
and internationally, and it is hard to precisely quantify the contribution made across the 
department to clinical trials. Some histopathology departments have a standard list of 
research costings, including those to cover specific pathologist activities (Supplementary 
table 2).  Appropriate funding is vital for provision of resources to improve clinical trial 
engagement, such as dedicated histopathologist time to oversee the clinical trials work and 
co-ordinate research opportunities for all staff. 
Whilst adequate resources and funding are pivotal, other potential alternative methods to 
recognise pathologists’ contribution include:  
• Authorship/ acknowledgement on publications 
• Certificate of participation/ appreciation from clinical trial investigators recognising the 
contribution of a pathologist to the trial 
• Support for pathologists’ applications to Clinical Excellence Awards or international 
equivalents 
• CPD accreditation: recognising the tasks and time spent on slide review, block selection, 
biomarker assessment 
• Mentorship: pairing up pathologists with varied expertise to enhance trial participation and 





 Clinical Trials Expertise and Regulation 
Histopathology staff providing support activity to a clinical trial must be adequately 
qualified, trained and experienced to assume clinical research responsibilities15. The research 
regulations, standards and guidelines that apply to pathology departments in the U.K. are 
reviewed in recent papers from CM-Path16,17. Clinical trials regulations and professional 
standards require staff to be trained commensurate with their roles and staff should be able to 
provide up-to-date training records and/or curriculum vitae. Whilst there is a lack of 
standardised training targeted at the needs of histopathologists, CM-Path and the RCPath in 
conjunction with organisations like the NIHR CRN are seeking to correct this via trials days 
and online resources. There is also a need for greater exposure to clinical trials as part of the 
histopathology training curriculum and more comprehensive CPD with respect to clinical 
trial development and delivery. In Europe, a joint ESP-EORTC fellowship program has been 
established to help young pathologists become active in trials and research18. A need for 
similar initiatives in other countries is recognised. 
Through CM-Path activities so far, there has been increased recognition of the importance of 
considering histopathology requirements during clinical trial design and better representation 
of histopathologists on the relevant committees. Its subgroup, the Clinical Trials - Pathology 
Advisory Group (CT-PAG) includes expert academic pathologists of various disciplines who 
not only offer advice to clinical trial designers on all aspects of tissue collection and testing, 
but to histopathologists and trainees as to how they can become more involved 
(cmpath.ncri.org.uk).  
Histopathologists may be unfamiliar with the regulatory requirements, which include the 




UK) or CE marking of in vitro diagnostic products in the context of personalised medicine by 
Notified Bodies. There are also inspections of facilities to ensure maintenance of the 
standards of Good Clinical Practice (GCP). GCP is particularly important for ensuring that 
the results of clinical trials are trustworthy and credible, and histopathologists involved in 
clinical research are often required to undertake additional specific training. It should be 
noted that regulatory standards and science continue to evolve, e.g. major amendments to the 
requirements for medical devices (including criteria for in vitro diagnostic approvals and the 
health institution exemption), and the soon to be implemented clinical trial regulation. 
Therefore, knowledge of the regulatory requirements requires regular review and 
implementation of all the relevant documents and standards. In areas of uncertainty scientific 
advice should be sought from local regulatory authorities, particularly if a development plan 
deviates from the recommendations found in published regulatory guidelines or if these 
documents are considered not to have sufficient detail, where new technologies are moving 
fast from the bench to the clinic (e.g. digital pathology with artificial intelligence 
algorithms19). These interactions require time and resource and are critical for the successful 
and efficient development of new drugs and diagnostics in the personalised medicine era.  
Summary and conclusion 
Pathology is key to clinical trials success and histopathologists actively contribute to trials as 
part of their routine work. Histopathology input is essential at each stage of trial design and 
delivery. Adequate resources and funding are urgently needed to enable greater engagement 
by pathologists in clinical trials. The SPIRIT-Path project is developing international, 
consensus-based, pathology-specific protocol guidance. CM Path is working closely with the 
RCPath and NCRI in the UK to find practical solutions, and to educate consultant 




personal and professional rewards gained by participation in clinical trials and subsequent 
improvements in delivery of patient care.   
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Figure 1:   Contribution of histopathologists at each stage of the clinical trial process 
Table 1: Examples of the role of histopathology in clinical trials including specific issues 
